Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Certified by Founder
Lodge
Reprieve Cardiovascular
start up
United States
- Milford, Massachusetts
- 21/02/2024
- Series A
- $42,000,000
Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure.
Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.
- Industry Medical Equipment Manufacturing
- Website https://reprievecardio.com/
- LinkedIn https://www.linkedin.com/company/reprieve-cardiovascular/
Gray Swan | $40,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
Countable Labs | $26,000,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
Reactor | $59,000,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)